HSINCHU,?Taiwan?and?WUHAN, China,??JHL Biotech?has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for its proposed trastuzumab biosimilar, JHL1188, to treat?breast cancer. The reference biologic trastuzumab is a humanized monoclonal antibody designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential when it is overexpressed. Given on its own as monotherapy, as well as in combination with or following standard chemotherapy, trastuzumab has been shown to improve overall survival, response rates, and disease-free survival while maintaining quality of life in women with HER2-positive breast cancer. The reference innovator biologic achieved approximately?US$7 billion?in sales globally in 2017 accordingly to publicly available sources. The EMA, like other regulatory authorities such as the U.S. Food and Drug Administration and State Drug Administration of?China?(SDA), adopts the principle of a step-wise approach and the totality of the evidence from all studies in regulating the development and approval of biosimilars. In its correspondence to JHL, the EMA confirmed it agrees with JHL's development approach, clinical development proposal, and study design of the global Phase III clinical study for JHL1188 in patients with metastatic breast cancer. Based on the EMA's review of these factors, the results of the Phase III clinical study will be acceptable for the submission of a Marketing Authorization Application as a biosimilar product, assuming the Phase III trial is completed successfully. About JHL Biotech
JHL Biotech, Inc. is a biopharmaceutical company founded by a group of industry veterans with deep experience in biologics development and operations. With a mission to provide the world with affordable medicines of exceptional quality, the company is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech's experienced leadership team, ongoing global clinical trials for its pipeline of biosimilar candidates and two?Asia-based world-class biologics manufacturing facilities built in accordance with?United States, European Union, and ICH cGMP regulations and standards uniquely position the company to be a leading global supplier of high quality biologics. JHL Biotech is backed by premier financial firms, including?Kleiner Perkins Caufield?& Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity and the China Development Industrial Bank. For more information, please visit?www.jhlbiotech.com. Media Contact
Jill Liu?| Email:?jliu@jhlbiotech.com?| Phone: +86-27-87879208
Amber Chen?| Email:?achen@jhlbiotech.com?| Phone: +886 3-658-3899
Lee Henely?| Email:?lhenely@jhlbiotech.com?| Phone: +886 3-658-3899 Forward-Looking Statement?
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. JHL undertakes no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond the control of either company. Actual results or outcomes may differ materially from those implied by the forward-looking statements.

Related Links

http://www.jhlbiotech.com SOURCE JHL Biotech